step semaglutide Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are 🚨 STEP UP Trial: Higher-dose

American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes 2026 Update

Results and What to Expect with Ipamorelin Therapy Most patients begin to notice subtle improvementssuch as better sleep and increased energywithin the first month of starting ipamorelin treatment

Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Sim R

Related Stories Eight-hour eating window sustains long-term weight loss Weight loss drugs may reduce binge eating disorder symptoms GLP-1 weight loss may reduce first-impression penalties in relationships and hiring Tirzepatide is a co-agonist of the GIP receptor and GLP-1R and demonstrates greater efficacy for weight loss and glucose lowering than selective GLP-1RAs, with a broadly similar adverse event profile

Connecticuts Warning Letter: Fix It Now Before We Escalate The Alabama Attorney Generals actions are consistent with those of the Connecticut Attorney General